Company Update Sanjivani Paranteral

Emerging from woods

Sanjivani Paranteral (SNJVP) is engaged in the manufacture and sale of pharmaceutical products. Established in October 1994 by a team of professionals helmed by Mr. Ashwani A Khemka, the company claims to be among the few pioneering parenteral and injectable businesses. It has two manufacturing plants at Navi Mumbai and Dehradun, specialising in the distribution of high-quality parenteral and oral solid products. After witnessing turbulence in FY16–20 due to heavy debts, this small size company reshaped its Balance Sheet by settling debts, infusing equity, and recouping its operating performance. It chalked out multiple plans for exponential growth in the mid-to-long term. We do not have a rating on the stock.

Emerging from the woods

SNJVP had been performing well before the devaluation of the Rubble in 2015 which resulted in it falling into a debt trap and defaulting on its loan repayments. At that time, nearly half of its business accrued from the Russian sub-continent. It supplied anti-TB drugs and nutraceuticals from its Dehradun facility, which was bought in FY09. This badly hit gearing and working capital finance and led to a net operating loss over FY16–20. It settled its debt by negotiating with an asset reconstruction company and issuing preferential shares in FY21 and FY22. As of September 30, 2023, it was nearly debt-free. However, equity expanded by ~69.5% over FY20–23 through a series of preferential issues.

Bolstering its base business

After reshaping its Balance Sheet, the management quickly expanded its product portfolio and geographical presence and built a strong product pipeline through collaborative R&D. Its CMO business (key clients include McLods, Gland Pharma, and Vita Biotics), which contributed ~4% of revenue in FY23) is growing steadily. The domestic branded business grew at a CAGR of 34% over FY19-23 and contributed 41% of revenue in FY23. It generated ~65% of revenue from exports to ~25 countries (mainly in the Middle East, Latin America, and CIS) in FY23. The company is focused on expanding its presence in LATAM. It is in the process of adding a few innovative products in the nutraceutical space which will significantly aid growth in the next couple of years.

Deal with Hindustan Antibiotics to be transformative:

It recently inked a significant agreement with Hindustan Antibiotics for the manufacture of IV formulations and IV sets on the latter's premises in Pimpri (Pune). The agreement is backed by a confirmed purchase commitment from Hindustan Antibiotics. The plant will have a monthly production capacity of 50lk IV fluid bottles and 10lk IV sets. The total investment for the project is ~INR50cr (including working capital). Production is likely to start by Q3FY25. We believe this business may gauge a peak revenue of INR100cr and may generate a healthy EBITDA margin of over 20%.

Setting up a manufacturing facility in Prague to target the European market

SNJVP has set up a JV with Prague's Alevia Healthcare to establish a new manufacturing and packaging facility for nutraceutical products. It will supply products manufactured in India to the Prague unit for packaging, leveling, and sale in Eastern Europe. It will invest INR6–7cr for a 45% stake in the JV which may generate a peak revenue of INR18–20cr and earn a decent EBITDA margin.

The latest financial results are encouraging

After the settlement of debt, its earnings turned around in FY21 and have been growing since then. In 9MFY24, it generated a revenue/EBITDA/PAT of INR41.54cr/INR6.1cr/INR4.91cr. In contrast, it posted a revenue/EBITDA/PAT of INR41.45cr/INR5.65cr/INR4.51cr in FY23.

Valuation and view

et a sur statu

SNJVP is undergoing a fresh spell of business transformation, with the focus shifting to de-risking the business. The same is being ushered by geographical diversification, portfolio augmentation, and B2B contracts (CMO and contracts with Hindustan Antibiotics). Assuming the contracts with Hindustan Antibiotics are executed as per schedule, we can expect revenue/ PAT to multiply by 4x/5x by FY26. We do not have any coverage on the stock.

Financials					
Year to March	FY20	FY21	FY22	FY23	9mFY24
Net Revenues (INR Cr)	16.4	25.1	30.6	35.5	41.5
% Growth (YoY)		53.5	22.0	15.9	51.8
EBITDA (INR Cr)	-0.3	2.1	5.7	5.6	6.1
EBITDA margin %	-2.0	8.5	18.7	15.9	14.6
Net Profit (INR Cr)	-1.7	1.4	4.8	4.5	4.9
Diluted EPS (INR)	-1.7	1.4	4.8	4.5	4.9
Diluted P/E (x)*	-87.8	105.7	30.9	33.2	22.9
EV/EBITDA (x)	-399.7	79.1	27.2	27.0	-
ROACE (%)	4%	-3%	-23%	-181%	-

*P/E ratio has been annualised



CMP: INR150 Rating: NA Date: March 28, 2024


Bloomberg:	SNJVP:IN
52-week range (INR):	29 /188
M-cap (INR cr):	178
Promoter holding (%)	27.67

Thakur Ranvir Singh ranvir.singh@nuvama.com




Revenue break (INR' Cr.)	FY19	FY20	FY21	FY22	FY23	CAGR (FY19-23)
Domestic	5.26	4.6	9.0	8.47	16.86	34
Contract Manufacturing and services	1.37	0.6	1.6	2.22	1.71	6
Direct Exports	17.73	10.9	14	19.22	22.65	6
Exports services	0.00	0.0	0	0.46	0.00	
Export incentives	0.73	0.3	-	0.24	0.25	-24
Total	25.1	16.4	25	30.6	41.5	13
Less: Branch Transfer					-5.98	
Net Revenue	25.09	16.36	25.10	30.61	35.49	9

Products-wise revenue break: Focus on injectables







Source: Nuvama Wealth Research



Financials

Income statement						(INR crs)
Year to March	FY19	FY20	FY21	FY22	FY23	9MFY24
Income from operations	25	16	25	31	35	42
Direct costs	15	9	15	12	19	24
Employee costs	3	3	2	3	3	3
Other expenses	9	5	6	9	8	9
Total operating expenses	27	17	23	25	30	35
EBITDA	-2	0	2	6	6	6
Depreciation and amortisation	1	1	1	1	1	1
EBIT	-3	-1	1	5	5	5
Interest expenses	0	1	0	0	0	0
Other income	1	0	0	0	1	0
Profit before tax	-2	-2	1	5	5	6
Provision for tax	0	0	0	0	0	1
Core profit	-2	-2	1	5	5	5
Extraordinary items	0	0	0	0	0	0
Profit after tax	-2	-2	1	5	5	5
Share from associates	0	0	0	0	0	0
Adjusted net profit	-2	-2	1	5	5	5
Equity shares outstanding (Crores)	0.6	0.6	0.8	1.0	1.0	1.0
EPS (INR) basic	-4	-3	2	5	5	5
Diluted shares (Cr)	1.0	1.0	1.0	1.0	1.0	1.0
EPS (INR) fully diluted	-2	-2	1	5	5	5

Common size metrics- as % of net revenues

Year to March	FY19	FY20	FY21	FY22	FY23	9MFY24
Operating expenses	107.0	102.0	91.5	81.3	84.1	85.4
Depreciation	4.7	6.6	3.4	2.9	2.5	1.7
Interest expenditure	1.3	4.0	0.5	0.7	1.0	0.4
EBITDA margins	(7.0)	(2.0)	8.5	18.7	15.9	14.6
Net profit margins	(8.2)	(10.4)	5.7	15.8	12.7	11.8

Growth metrics (%)

Year to March	FY19	FY20	FY21	FY22	FY23	9MFY24
Revenues		(34.8)	53.5	22.0	15.9	51.8
EBITDA		(81.1)	(744.3)	167.5	(1.5)	44.4
РВТ		(21.2)	(178.1)	245.5	1.3	44.1
Net profit		(17.4)	(183.1)	241.5	(6.9)	39.6
EPS		(17.4)	(183.1)	241.5	(6.9)	39.6



Balance sheet						(INR cr)
As on 31st March	FY19	FY20	FY21	FY22	FY23	H1FY24
Equity share capital	6	6	8	10	10	10
Reserves & surplus	-53	-55	-53	-18	-13	-10
Shareholders' funds	-47	-49	-45	-8	-3	0
Borrowings	45	45	42	6	2	1
Net Deferred tax	1	1	1	1	0	0
Sources of funds	-1	-3	-2	-1	-0	1
Gross block	22	22	22	23	24	26
Depreciation	13	14	14	15	16	17
Net block	9	8	8	7	8	10
Capital work in progress	0	0	0	0	0	0
Right of Use Assets	0	0	0	0	0	0
Total fixed assets	9	8	8	7	8	10
Intangible	0	0	0	0	0	0
Investments	0	0	0	0	0	0
Inventories	1	2	1	2	5	4
Sundry debtors	5	3	7	5	2	7
Cash and equivalents	0	0	0	0	0	0
Loans and advances	1	1	2	2	4	0
Other current assets	0	1	1	0	0	2
Total current assets	8	7	11	10	12	14
Sundry creditors and others	18	18	20	18	20	22
Provisions	1	1	1	1	1	1
Total CL & provisions	19	19	21	19	21	23
Net current assets	-12	-13	-11	-9	-9	-9
Other Non-Current Assets	1	1	1	1	1	0
Uses of funds	-1	-3	-2	-1	-0	1
Book value per share (INR)	-80	-83	-53	-8	-3	0

Cash flow statement						(INR cr)
Year to March	FY19	FY20	FY21	FY22	FY23	H1FY24
Net profit	-2	-2	1	5	5	3
Add: Depreciation	1	1	1	1	1	0
Add: Deferred tax	-0	-0	-0	0	-1	0
Gross cash flow	-1	-1	2	6	5	4
Less: Changes in W. C.	0	-2	6	-2	-2	4
Operating cash flow	-1	-2	8	3	3	8
Less: Capex	0	0	0	1	1	-3
Free cash flow	-1	-2	7	3	2	10

Nuvama Group has two independent equity research groups: Institutional Equities and Professional Clients Group. This report has been prepared by the Professional Clients Group.



Ratios

Year to March	FY19	FY20	FY21	FY22	FY23	H1FY24
ROAE (%)	4%	4%	-3%	-18%	-85%	28%
ROACE (%)	8%	4%	-3%	-23%	-181%	3%
Debtors (days)	76	24	96	59	20	101
Current ratio	0	0	0	0	0	1
Debt/Equity	-1	-1	-1	-1	-1	4
Inventory (days)	8	37	13	21	55	61
Payable (days)	176	241	154	136	141	211
Cash conversion cycle (days)	-92	-180	-44	-57	-66	-49
Net Debt/EBITDA	-25	-133	19	1	0	0
Net debt/Equity	-1	-1	-1	-1	-1	3

Valuation parameters

Year to March	FY19	FY20	FY21	FY22	FY23	H1FY24
Diluted EPS (INR)	(2.1)	(1.7)	1.4	4.8	4.5	3.3
Y-o-Y growth (%)		(17.4)	(183.1)	241.5	(6.9)	(27.8)
CEPS (INR)	-2	-1	3	6	5	4
Diluted P/E (x)*	(72.6)	(87.8)	105.7	30.9	33.2	23.0*
Price/BV(x)	(1.9)	(1.8)	(2.8)	(19.8)	(48.8)	811.1
EV/Sales (x)	5.3	8.1	6.7	5.1	4.3	5.7
EV/EBITDA (x)	(75.7)	(399.7)	79.1	27.2	27.0	36.5
Diluted shares O/S	0.6	0.6	0.8	1.0	1.0	1.0
Basic EPS	(3.5)	(2.9)	1.7	4.9	4.5	3.3
Basic PE (x)	(42.9)	(51.7)	89.8	30.9	33.3	23.0*

*P/E ratio has been annualised



Nuvama Wealth and Investment Limited, Eight Floor 801 to 804, Inspire BKC G Block, BKC Main Road, Bandra Kurla Complex, Bandra East, Mumbai-400051

Sandeep Raina

Head of Research – Professional Client Group

sandeep.raina@nuvama.com



Nuvama Wealth and Investment Limited (Formerly known as Edelweiss Broking Limited) ("NWIL") or ("Research Entity") a company duly incorporated under the Companies Act, 1956 (CIN No U65100GJ2008PLC077462) having its Registered office situated at 201 to 203, Zodiac Plaza, Xavier College Road, Off C G Road, Ahmedabad, Gujarat - 380009. It is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of NWIL and its Associates (list available on www.nuvamawealth.com) are organized around five broad business groups: Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance

Broking services offered by Nuvama Wealth and Investment Limited under SEBI Registration No. INZ 000005231. Name of the Compliance Officer: Mr Srijith Menon, Email address: complianceofficer.nwil@nuvama.com. Corporate Office Eight Floor 801 to 804, Inspire BKC G Block, BKC Main Road, Bandra Kurla Complex, Bandra East, Mumbai-400051

This Report has been prepared by Nuvama Wealth and Investment Limited (Formerly Edelweiss Broking Limited) [NWIL] in the capacity of a Research Analyst having SEBI Registration No. INH000011103 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWIL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWIL reserves the right to make modifications and alterations to this statement as may be required from time to time. NWIL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWIL is committed to providing independent and transparent recommendation to its clients. Neither NWIL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment dusinos statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. T

NWIL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWIL to present the data. In no event shall NWIL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWIL through this report. We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWIL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWIL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d). The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWIL. (e) Registration granted by SEBI and certification from NISM in no way guarantee performance of NWIL or provide any assurance of returns to investors and clients.

NWIL or its associates may have received compensation from the subject company in the past 12 months. NWIL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWIL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWIL or its associates may have received any compensation for products or services other than investment banking or merchant banking or merchant banking or brokerage services from the subject company in the past 12 months. NWIL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWIL's associates may have financial interest in the subject company. NWIL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

NWIL has financial interest in the subject companies: No

NWIL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Disclaimer



Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWIL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWIL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

DISCLAIMERS FOR INTERNATIONAL JURISDICTION

Disclaimer for U.S. Persons

The content of the website does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules. THIS DOCUMENT IS INTENDED SOLELY TO PROVIDE INFORMATION TO THE QUALIFIED INSTITUTIONAL INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. This communication is intended solely for the person to whom it is addressed and may contain confidential or privileged information. The document is intended to be educational only and not for a marketing or prospecting purpose. The views and opinions expressed as part of this presentation do not necessarily state or reflect those of Nuvama, its holding company(ies), subsidiaries and associates including entities in overseas jurisdictions.

The content of the website or any information contained therein must not be distributed, published, reproduced, or disclosed (in whole or in part) by recipients to any other person. The content of the website must not be acted on or relied on by persons who are not qualified institutional investor. Any investment or investment activity to which this website relates, is available only to qualified institutional investor and will be engaged only with qualified institutional investor. Any person who is not a qualified institutional investor should not act or rely on this website or any of its contents

Disclaimer for U.K. Persons:

The content of the website has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). In the United Kingdom, this document is intended for (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). THIS document IS INTENDED SOLELY TO PROVIDE INFORMATION TO THE QUALIFIED INSTITUTIONAL INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. This communication is intended solely for the person to whom it is addressed and may contain confidential or privileged information. The content of the document is intended to be educational only and not for a marketing or prospecting purpose. The views and opinions expressed as part of this document do not necessarily state or reflect those of Nuvama, its holding company (ies), subsidiaries and associates including entities in overseas jurisdictions.

Disclaimer for Canadian Persons

The content of the website is NOT MEANT FOR RETAIL INVESTORS. IT IS INTENDED SOLELY TO PROVIDE INFORMATION TO THE PERMITTED CLIENTS ONLY (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). Any products or services described in this document are made available only in accordance with applicable Canadian securities law and only where they may be lawfully offered for sale. If the person accessing this document is not an Ontario Permitted Client, as specified above, then the recipient should not access the same. Nuvama and its group companies is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) Nuvama and its group companies is not registered in the Province of Ontario to trade in securities nor is it registered in the Province of Ontario to provide advice with respect to securities; (ii) Nuvama's head office or principal place of business is located in India; (iii) all or substantially all of Nuvama's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against Nuvama because of the above; and (v) the name and address of Nuvama Group's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario MSJ 2T3 Canada. The content of the website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. This communication must not be acted on or relied on by persons who are not PERMITTED CLIENTS. Any investment or investment activity to which this communication or any of its contents.

Disclaimer for UAE Persons

The content of the website is INTENDED SOLELY TO PROVIDE INFORMATION TO THE INSTITUTIONAL QUALIFIED INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS. Further, the information in this document does not constitute a public offer of securities in the United Arab Emirates and is not intended to be a public offer. The website has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority of the United Arab Emirates or the Dubai Financial Services Authority. The content of the website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. The website must not be acted on or relied on by persons who are not INSTITUTIONAL QUALIFIED INVESTORS. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any published, reproduced or disclosed (in whole or in part) by recipients to any other person. The website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. The website must not be acted on or relied on by persons who are not nelevant persons. Any person who is not a INSTITUTIONAL QUALIFIED INVESTORS should not act or rely on this communication or any of its contents. The content of the website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. The website must not be acted on or relied on by persons who are not relevant persons. Any investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

Disclaimer



Disclaimer for Australia Persons

Any information set out on the website is only intended for persons who are "Professional Investors" as described in Section 761(G) of the Corporations Act 2001 (as amended). It is not intended to for any other class of persons and may not be relied upon by such persons and is therefore not intended for private individuals or those who would be classified as Retail Clients. All information on the website is general information only and is not to be considered any form of advice (whether investment or otherwise) or a recommendation, solicitation, or an offer to purchase or sell investments or related financial products or any financial services. The receiver of the website should make their own decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an appropriate independent advisor. Nuvama and its group companies does not hold an Australian Financial Services License and is not licensed in Australia to provide financial product advice or services and is relying on "limited connection relief exemption" when dealing with "Professional Investors" (Wholesale client category) in Australia.

Disclaimer for Singapore Persons

The content of the website IS INTENDED SOLELY TO PROVIDE INFORMATION ONLY TO THE INSTITUTIONAL OR ACCREDITED INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS AS DEFINED UNDER THE SECURITIES AND FUTURES ACT "SFA". If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. Any such information contained or discussed in the document is subject to change and Nuvama and its group companies shall not have any responsibility to maintain the information made available or to supply any correction therewith. In no event will Nuvama and its group companies be liable for any special direct or indirect or consequential damages which may be incurred from the use of the information made available, even if it has been advised of the possibility of such damages. The company and its employees mentioned in these communications cannot be held liable for any error's inaccuracies and/or omission howsoever caused. Any opinion or advice if any herein is made on a general basis and is subject to change without notice. The information provided in this document may contain optimistic statements regarding future events or future financial performance of countries, markets, or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided if any in this document. This document has not been reviewed by the Monetary Authority of Singapore "MAS".

Additional Marketing Disclaimer for all other International Jurisdiction:

The content of this website is restricted in certain jurisdictions and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, by anyone in any jurisdiction in which such an offer or solicitation is not authorised or may not lawfully be made (without compliance with any registration or other legal requirements) or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such offer in any jurisdiction. The above information is for general guidance only, it is the responsibility of receivers to inform themselves as to any income or other tax consequences arising in the jurisdictions in which they are resident or domiciled or have any other presence for tax purposes, as well as any foreign exchange or other fiscal, or legal or regulatory restrictions which are relevant to their particular circumstances in connection with the acquisition, holding or disposal of any securities if any mentioned in this document. This document is strictly private and confidential and may not be reproduced or use for any other purpose and not be provided to any person other than the recipient thereof. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. Any such information contained or discussed on the website is subject to change and Nuvama Group or any of its Directors, Employees, agents or representatives shall not have any special direct or indirect or indirect or consequential damages which may be incurred from the use of the information made available, even if it has been advised of the possibility of such damages. The company and its precession howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in this website may contain optinistic statement

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.